TICKERNERD
Menu
BHVNBHVNHealthcare · Biotechnology

BHVN Stock Forecast: Biohaven Ltd. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$15
−6.49% on the day

The 17 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $22 — +42.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$2.5B
Ticker Nerd rank
53/ 100
Median analyst target
$22
Analysts covering
17
Revenue$0.0
Operating income−$124.9M
Net income−$137.3M
Free cash flow−$85.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.1%
1M
+15.5%
YTD
+36.6%
1Y
−11.3%
From 52W high
−11.3%
From 52W low
+97.9%
$8
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BHVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
53/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
78
Accruals
76
Revisions
61
Issuance
59
Value
57
Momentum
48
Volatility
35
Size
33
Quality
16

Growth (78): Sales and profits are climbing, and climbing faster than before.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BHVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26BHVNHigh $48Median $22Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
12 Buy4 Hold1 Sell
Low $10Median $22High $48

The green dot is the last close — the median target sits +42.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
23 Oct 2026RBC CapitalMaintainsSector Perform$19 → $22
10 Sept 2026HC Wainwright & Co.ReiteratesNeutral$10
10 Sept 2026HC Wainwright & Co.ReiteratesNeutral—
8 Sept 2026RBC CapitalDowngradeSector Perform$23 → $19
8 Sept 2026RBC CapitalDowngradeSector Perform—
12 Aug 2026Morgan StanleyMaintainsOverweight$18 → $19
12 Aug 2026Morgan StanleyMaintainsOverweight—
11 Aug 2026RBC CapitalMaintainsOutperform$22 → $23
11 Aug 2026RBC CapitalMaintainsOutperform—
29 June 2026B of A SecuritiesDowngradeUnderperform$12 → $11
29 June 2026B of A SecuritiesDowngradeUnderperform—
26 May 2026HC Wainwright & Co.ReiteratesNeutral—
13 May 2026Morgan StanleyMaintainsOverweight—
5 May 2026RBC CapitalMaintainsOutperform—
2 Apr 2026CitigroupMaintainsBuy—
11 Mar 2026TD CowenMaintainsBuy—
4 Mar 2026HC Wainwright & Co.MaintainsNeutral—
3 Mar 2026RBC CapitalMaintainsOutperform—
21 Jan 2026RBC CapitalUpgradeOutperform—
6 Jan 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BHVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BHVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Biohaven Ltd. returned −11.3% against +12.4% for the S&P 500, dividends included.

BHVN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26BHVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BHVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Biohaven Ltd. (BHVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
192.0×

Cheaper than 1% of US stocks

EV / EBITDA
−4.8×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−799.5%

Higher than 2% of US stocks

Return on assets
−72.0%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biohaven Ltd. (BHVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biohaven Ltd. has a market value of $2.5B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$586.8M.

  • Diluted earnings per share, trailing twelve months: $−4.64.

  • Free cash flow in the twelve months to 30 June 2026: −$511.9M.

  • Shares outstanding: 151.0M.

  • Trailing P/E: −2.3×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Biohaven Ltd. employs 274 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

BHVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BHVNBiohaven Ltd.$2.5B53
HRMYHarmony Biosciences Holdings, Inc.$2.2B84
XNCRXencor, Inc.$2.2B85
AUPHAurinia Pharmaceuticals, Inc.$2.2B98
NAMSNewAmsterdam Pharma Co. NV$2.3B46
VERAVera Therapeutics, Inc.$2.2B27
CLDXCelldex Therapeutics, Inc.$2.3B25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BHVN news & analysis

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

PRNewsWire · 29 Oct 2026positive

Biohaven said the FDA accepted its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, with a user fee goal date in the first quarter of 2027. The company also announced an exclusive global license with SK Biopharmaceuticals.

Why it matters — The update covers a regulatory milestone for Vyglxia and a newly announced licensing agreement relevant to Biohaven's business.

Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade

Zacks Investment Research · 29 Oct 2026positive

Analysts’ average price targets indicate a potential 43.5% upside for Biohaven Ltd. (BHVN), though the excerpt notes the metric’s effectiveness is questionable. Positive trends in earnings estimate revisions may also translate into upside for the stock.

Why it matters — BHVN watchers may note both the analyst price-target signal and the caveat about its reliability, alongside improving earnings estimate revisions.

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

PRNewsWire · 26 Oct 2026positive

Biohaven said its oral presentation at ASN Kidney Week 2026 will spotlight BHV-1420, an investigational TRAP extracellular protein degrader for membranous nephropathy. The company says it is designed to bind anti-PLA2R autoantibodies and direct them to the liver for degradation without immunosuppression.

Why it matters — BHVN watchers may note the presentation as an update on the company’s kidney-disease TRAP degrader platform and its expansion into nephrology.

Biohaven Rebounds With FDA Review Date for Rare Disease Drug

Benzinga · 22 Oct 2026positive

Biohaven’s stock rose Thursday after an update on its spinocerebellar ataxia (SCA) program, with reported session volume of 10.293 million shares compared with an average of 2.585 million. The headline says the update included an FDA review date for a rare disease drug.

Why it matters — The FDA review date and SCA program update are relevant developments for investors following Biohaven’s rare disease drug program.

FAQ

Frequently asked questions about BHVN stock

What is the BHVN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $22, with estimates ranging from $10 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BHVN stock a buy right now?

Of the 17 analysts covering Biohaven Ltd., 12 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 53 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BHVN?

As at 31 Oct 2026, Biohaven Ltd. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).

Will BHVN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +42.7% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 53 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BHVN stock forecast for 2030?

No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $48 over the next 12 months.

How has BHVN stock performed over the past year?

Biohaven Ltd. returned -11.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biohaven Ltd. do?

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.

What is the latest news on BHVN?

The most recent item we track (PRNewsWire, 29 Oct 2026): "Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results". Biohaven said the FDA accepted its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, with a user fee goal date in the first quarter of 2027. The company also announced an exclusive global license with SK Biopharmaceuticals.

Company

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.

CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com